Evotec, CDP Venture Capital and Angelini Ventures launch “Extend” translational partnership with leading Italian academic institutions
HAMBURG, GERMANY/ACCESSWIRE/October 28, 2022/ Evotec SE (Frankfurt Stock Exchange:EVT)(MDAX/TecDAX)(ISIN:DE0005664809)(NASDAQ:EVO today announced the launch of “Extend”, a translational BRIDGE partnership in cooperation with CDP Venture Capital Sgr, a strategic pillar of the Italian economy for growth and innovation, and Angelini Ventures, the Corporate Venture Capital branch of the multi-business industrial group Angelini Industries.
Extend is a joint venture between Evotec, CDP Venture Capital and Angelini Ventures to develop translational drug discovery partnerships with renowned universities and research centers in Italy. Extend aims to use Evotec’s best-in-class technology platforms to accelerate the translation of academic innovation into robust, investable data points and Angelini Ventures’ network and knowledge of the life sciences industry to launch successful new ventures. .
The partnership brings together several academic institutions with solid experience in life science innovation from all over Italy: Ospedale San Raffaele in Milan, the universities of Milan, Florence, Modena and Reggio Emilia, Padua, Sapienza in Rome, the regional research district of Puglia through H-Bio and the Human Technopole. Extend will be located in the MIND district of Milan, the new center of scientific excellence in Italy focused on life sciences.
Evotec’s BRIDGE (Biomedical Research, Innovation & Development Generation Efficiency) collaborations provide an integrated framework of funds and awards to validate exciting academic projects in collaboration with pharmaceutical, biotechnology and venture capital partners with the aim of creating new businesses.
Dr. Werner Lanthaler, Managing Director of Evotec, said: “We are delighted to launch Extend with our partners at CDP Venture Capital and Angelini Ventures. The university sector in Italy has always been a driver of innovation on a global scale. Extend offers researchers from member institutions a unique way to Accelerate – track their projects, validate them on our industry-grade platform, and create partnership options that include building new businesses.”
Enrico Resmini, CEO and Managing Director of CDP Venture Capital, said: “The launch of the Extend National Technology Transfer Hub adds a key step in the path we are building to bridge the Italian technology transfer gap and open university laboratories to international markets. The pharmaceutical and drug discovery sectors represent the ‘one of the most vivid examples of how cutting-edge research and technology can shape people’s lives in a short time, as we have all experienced first-hand during the health emergency.”
Professor Sergio Marullo di Condojanni, CEO of Angelini Industries, added: “We are delighted to be part of the creation of Polo Extend with high-level partners in the biotechnology and innovation sectors. Being involved in this project represents an important opportunity for Angelini Industries to contribute to the development of the ecosystem of innovation, of which Extend represents a virtuous example. The participation of Angelini Ventures, under the leadership of CEO and Managing Director Paolo Di Giorgio, underlines our desire to strengthen the bridge between the excellence of Italian academic research and the development of drug discovery programs to identify new treatment options”
About the extension
Extend is a BRIDGE translational joint venture founded by Evotec, CDP Venture Capital and Angelini Ventures in 2022. Extend brings together leading Italian academic institutions to accelerate the commercialization of their most promising assets. To learn more about Extend, visit www.extend-tthub.com.
“This partnership demonstrates the excellence and attractiveness of the University of Milan in research in the life sciences. It seizes the opportunity to translate the discoveries and innovations of our scientific community into tangible improvements in the quality people’s lives, advancing preclinical projects to the level required to compete in the marketplace. My hope is that, in this way, our university can make a tangible contribution to technology transfer as a key mission for public researchers,” said Maria Pia Abbracchio, vice-rector for research coordination and promotion at the University of Milan.
Professor Gianvito Martino, Scientific Director of IRCCS Ospedale San Raffaele in Milan, said: “The creation of the Extend Hub demonstrates once again to what extent the pharmaceutical sector is the one in which university-industry partnerships are being consolidated the most on a global level. We warmly welcome this initiative, in which we participate with conviction, because We believe that it is precisely in this area that collaboration between research, industry and the financial sector – even with the creation of start-ups – is an essential way to be truly competitive internationally”.
About Evotec’s BRIDGE Model: Partnering to Accelerate Innovation
Evotec has created a new paradigm for translating early-stage academic research into drug discovery and development called “BRIDGE” (Biomedical Research, Innovation & Development Generation Efficiency), an integrated framework of funds and awards to tap into academic science to accelerate the formation of spin-out companies and generate collaborations with Pharma and biotech. Through these efforts, Evotec has defined a new formula for accelerated early-stage drug discovery. Since the launch of the BRIDGE model in 2016, Evotec has formed and funded a number of different collaborations, for example LAB282, LAB150, Autobahn-Labs, Argobio, beLAB2122, beLAB1407 and Danube Labs. Please visit www.evotec.com/en/innovate/bridges to learn more about Evotec’s BRIDGE.
ABOUT CDP VENTURE CAPITAL
CDP Venture Capital is an asset management company (70% owned by CDP Equity and 30% by Invitalia) with more than €1.8 billion in assets under management. It aims to make venture capital a strategic pillar of Italy’s economic development and innovation, creating the conditions for a global and sustainable growth of the venture capital ecosystem. It operates through a series of funds that aim to support start-ups at all stages of their life cycle, making direct and indirect investments.
ABOUT ANGELINI VENTURES
Angelini Ventures is a global investment group that creates and invests in innovative solutions and ideas in biotechnology, life sciences and digital health.
Angelini Ventures will invest in Europe, North America and Israel focusing on central nervous system, mental health and market segments focused on women, children and the elderly. The company is based in Rome and has a global team made up of an international network of innovation experts.
Angelini Ventures is part of Angelini Industriesthe international industrial group present in 21 countries, with 5,800 employees and an annual turnover of 1.7 billion euros.
Angelini Industries operates in the fields of pharmaceuticals, consumer goods, industrial technologies, perfumes and dermo-cosmetics, wine and venture capital. For more information, please visit angeliniventures.com
ABOUT EVOTEC SE
Evotec is a life sciences company with a unique business model that pursues its mission to discover and develop highly effective treatments and bring them to patients. The Company’s multi-modality platform includes a unique combination of innovative technology, data and science for the discovery, development and production of first-class, first-class pharmaceuticals. Evotec leverages this “data-driven R&D highway to cure” for proprietary projects and within a network of partners including all Top 20 Pharma and over 800 biotech companies, academic institutions, as well as other health actors. Evotec has strategic activities in a wide range of currently underserved therapeutic areas, including neurology, oncology, as well as metabolic and infectious diseases. Within these areas of expertise, Evotec aims to create the world’s first pipeline of innovative co-owned therapeutics and has to date established a portfolio of over 200 proprietary and co-owned R&D projects, from early discovery to clinical development. Evotec operates worldwide with over 4,500 highly skilled people. The Company’s 16 sites offer highly synergistic technologies and services and function as complementary centers of excellence. For more information, visit www.evotec.com and follow us on Twitter @Evotec and LinkedIn.
This announcement contains forward-looking statements regarding future events, including the proposed offering and listing of Evotec’s securities. Words such as “anticipate”, “believe”, “could”, “estimate”, “expect”, “intend”, “may”, “could”, “plan”, “potential”, “should”, “target”, ” ” and variations of these words and similar expressions are intended to identify forward-looking statements. These statements include comments regarding Evotec’s expectations for revenue, group EBITDA and non-partnership R&D expenditure. These forward-looking statements are based on currently available information and on expectations and assumptions that Evotec believed were reasonable at the time such statements were made. No assurance can be given that these expectations will prove to be correct. These statements involve known and unknown risks and are based on a number of assumptions and estimates, which are inherently subject to significant uncertainties and contingencies, many of which are beyond Evotec’s control. Evotec expressly disclaims any obligation or undertaking to publicly release any updates or revisions to any forward-looking statements contained herein to reflect any change in Evotec’s expectations with respect thereto or any change in events, conditions or circumstances about which any statement is based.
Evotec SE media contact:
Gabriele Hansen, SVP Head of Global Corporate Communications, Phone: +49.(0)40.56081-255, [email protected]
Hinnerk Rohwedder, Senior Specialist Corporate Communications, Tel. : +49.(0)151 4070-4843, [email protected]
Evotec SE IR contact:
Volker Braun, SVP Head of Global Investor Relations & ESG, Phone: +49.(0)40.56081-775, [email protected]
THE SOURCE: Evotec SE
See the source version on accesswire.com: